Inclusion Criteria:  Main prescription data analysis:  - At least one prescription for lisdexamfetamine dimesylate recorded in the NostraData database in Australia.  For all sensitivity analyses (sensitivity analysis I, II and III):  - At least one prescription for lisdexamfetamine dimesylate recorded in the NostraData database in Australia during the defined observation period of the study.  Physician survey:  - The physician prescribed lisdexamfetamine dimesylate for indications other than ADHD in the last 12 months for at least one participant.  Participant population:  - Physician entered data for the participant until at least question 3 (treatment information (Q03); main indication).  Exclusion Criteria:  For all sensitivity analyses (sensitivity analysis I, II and III):  Evidence of use for lisdexamfetamine dimesylate for treatment of ADHD, as shown by prescription records for ADHD medication other than lisdexamfetamine dimesylate at any time. Record of at least one lisdexamfetamine dimesylate prescription prior to launch of lisdexamfetamine dimesylate for BED (02/17/2018).  Additional exclusion criteria for the specific sensitivity analyses:  For sensitivity analysis I:  - Prescriptions for lisdexamfetamine dimesylate issued by pediatricians or child psychiatrists.  For sensitivity analysis II:  - Prescriptions for lisdexamfetamine dimesylate issued by all prescribers other than psychiatrists (example, pediatricians, general practitioner [GPs]).  For sensitivity analysis III:  Prescriptions for lisdexamfetamine dimesylate issued by pediatricians or child psychiatrists. For participants with age available, participants with evidence for age at first prescription below 18 years.  Physician survey and participant population:  - Physician entered ADHD as main indication for prescription of lisdexamfetamine dimesylate (treatment information [Q03]) for the participant.